share_log

Barclays Maintains Equal-Weight on Beam Therapeutics, Lowers Price Target to $33

Barclays Maintains Equal-Weight on Beam Therapeutics, Lowers Price Target to $33

巴克莱对Beam Therapeutics保持同等权重,将目标股价下调至33美元
Benzinga ·  05/08 14:03

Barclays analyst Gena Wang maintains Beam Therapeutics (NASDAQ:BEAM) with a Equal-Weight and lowers the price target from $42 to $33.

巴克莱分析师Gena Wang维持Beam Therapeutics(纳斯达克股票代码:BEAM)的权重相等,并将目标股价从42美元下调至33美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发